Efficacy and Safety of AZD7009 in the Treatment of Atrial Fibrillation
Launched by ASTRAZENECA · Nov 17, 2005
Trial Information
Current as of May 28, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Clinical indication for cardioversion of Atrial Fibrillation. Effective oral anticoagulation according to local routines or a TEE without any finding of intracardial thrombus or signs of thrombogenecity
- Exclusion Criteria:
- • Clinically significant sinus and/or AV node dysfunction. Serum or plasma potassium \<3.8 mmol/L or \>5.0 mmol/L. QTc(Bazett) \>450 ms. Any QRS duration \>150 ms
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Hamburg, , Germany
Opole, , Poland
Warszawa, , Poland
Stockholm, , Sweden
Helsinki, , Finland
Aachen, , Germany
Groningen, , Netherlands
Oslo, , Norway
Tromso, , Norway
Trondheim, , Norway
Magdeburg, , Germany
Kecskemet, , Hungary
Esbjerg, , Denmark
Hellerup, , Denmark
Wroclaw, , Poland
Hvidovre, , Denmark
Svendborg, , Denmark
Cegled, , Hungary
Maastricht, , Netherlands
Oulu, , Finland
Brandenburg, , Germany
Szentes, , Hungary
Stadskanaal, , Netherlands
Szekesfehervar, , Hungary
Bytom, , Poland
Linkoping, , Sweden
Rud, , Norway
Bad Berka, , Germany
Munster, , Germany
Ruda Slaska, , Poland
Orebro, , Sweden
Patients applied
Trial Officials
AstraZeneca AZD7009 Midical Science Director, MD
Study Director
AstraZeneca
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials